Skip to content

Released May 5, 2026, before the open

10-Q filed May 5, 2026, 35 days after period end · 0001171843-26-003006

Q1 2026 · 10-Q
Revenue—
Net Income-$18.32MN/M vs Q1 2025N/M vs Q4 2025
EPS, diluted—
Operating Income-$20,299,000N/M
Operating Cash Flow-$17,269,000N/M
Free Cash Flowderived-$17,351,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Net Income-$18.32M-$16.63M-$10.79M-$7.84M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR